Align Technology (ALGN) has seen a mix of performance and investor activity. Since the last earnings report, the company's stock has increased by 5.5%, with Natixis Advisors LLC purchasing 3,344 shares. Furthermore, ALGN has received CE mark approval in Europe for the Invisalign Palatal Expander System following a stock rise and declaration of a winning financial formula. However, it wasn't all smooth sailing, with the company's stock underperforming the market and aligner demand leading to missed third-quarter revenue estimates. Other developments include Eagle Asset Management Inc. selling 122,553 shares and ALGN planning to present at the Jefferies London Healthcare Conference.
Despite declination in earnings over three years, ALGN continues to innovate, opening a 2025 Annual Research Program and announcing a $275 million open market repurchase. However, the company took a hit after a mixed quarterly report, falling behind in returns on capital. The company faced lower sales view in Q2, but managed to beat earnings estimate. Nonetheless, 2024 Q3 earnings missed expectations, blighting perceived momentum.
Align Technology ALGN News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 23 Nov 2024 11:13:06 GMT -
